Theravance Biopharma Past Earnings Performance
Past criteria checks 0/6
Theravance Biopharma has been growing earnings at an average annual rate of 18.9%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been declining at an average rate of 6.2% per year.
Key information
18.9%
Earnings growth rate
23.8%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | -6.2% |
Return on equity | -25.9% |
Net Margin | -96.1% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S
Feb 05Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts
Nov 11Theravance to purchase $95M of ordinary shares
Sep 28Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade
Sep 21Theravance Biopharma announces $250M capital return program
Sep 19Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M
Aug 04Theravance: All-Round Failure
Mar 10Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%
Aug 09Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study
Jun 21Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year
May 09Theravance Biopharma EPS misses by $0.16, misses on revenue
May 04Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why
Apr 21Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)
Mar 13Is Theravance Biopharma, Inc. (NASDAQ:TBPH) Expensive For A Reason? A Look At Its Intrinsic Value
Mar 08Revenue & Expenses BreakdownBeta
How Theravance Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 57 | -55 | 70 | 0 |
30 Sep 23 | 55 | -61 | 71 | 0 |
30 Jun 23 | 51 | -68 | 71 | 0 |
31 Mar 23 | 49 | -75 | 68 | 0 |
31 Dec 22 | 51 | -93 | 67 | 0 |
30 Sep 22 | 52 | -136 | 72 | 0 |
30 Jun 22 | 52 | -196 | 77 | 0 |
31 Mar 22 | 54 | -226 | 87 | 0 |
31 Dec 21 | 55 | -265 | 99 | 0 |
30 Sep 21 | 59 | -266 | 108 | 0 |
30 Jun 21 | 64 | -264 | 114 | 0 |
31 Mar 21 | 66 | -275 | 113 | 0 |
31 Dec 20 | 72 | -295 | 109 | 0 |
30 Sep 20 | 83 | -285 | 112 | 0 |
30 Jun 20 | 77 | -270 | 110 | 0 |
31 Mar 20 | 88 | -247 | 107 | 0 |
31 Dec 19 | 73 | -236 | 106 | 0 |
30 Sep 19 | 60 | -221 | 98 | 0 |
30 Jun 19 | 60 | -222 | 95 | 0 |
31 Mar 19 | 57 | -223 | 98 | 0 |
31 Dec 18 | 60 | -216 | 97 | 0 |
30 Sep 18 | 49 | -252 | 101 | 0 |
30 Jun 18 | 41 | -260 | 100 | 0 |
31 Mar 18 | 21 | -285 | 100 | 0 |
31 Dec 17 | 15 | -285 | 96 | 0 |
30 Sep 17 | 17 | -266 | 86 | 0 |
30 Jun 17 | 31 | -233 | 86 | 0 |
31 Mar 17 | 33 | -214 | 82 | 0 |
31 Dec 16 | 49 | -191 | 85 | 0 |
30 Sep 16 | 47 | -168 | 88 | 0 |
30 Jun 16 | 38 | -182 | 91 | 0 |
31 Mar 16 | 40 | -182 | 92 | 0 |
31 Dec 15 | 42 | -182 | 90 | 0 |
30 Sep 15 | 40 | -202 | 88 | 0 |
30 Jun 15 | 35 | -209 | 83 | 0 |
31 Mar 15 | 31 | -219 | 74 | 0 |
31 Dec 14 | 12 | -237 | 72 | 0 |
30 Sep 14 | 10 | -217 | 62 | 0 |
30 Jun 14 | 4 | -203 | 53 | 0 |
31 Mar 14 | 1 | -184 | 48 | 0 |
31 Dec 13 | 0 | -156 | 36 | 0 |
30 Sep 13 | 5 | -141 | 31 | -74 |
30 Jun 13 | 5 | -133 | 28 | -48 |
Quality Earnings: TBPH is currently unprofitable.
Growing Profit Margin: TBPH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TBPH is unprofitable, but has reduced losses over the past 5 years at a rate of 18.9% per year.
Accelerating Growth: Unable to compare TBPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TBPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: TBPH has a negative Return on Equity (-25.91%), as it is currently unprofitable.